Company News

Abstract Posters and Presentations Featuring MyoStrain at AHA Virtual Scientific Sessions 2021

December 16, 2021
Company News

MORRISVILLE, N.C., December 16, 2021 – Three abstracts utilizing MyoStrain, Myocardial Solutions’ patented technology, were accepted and presented at the distinguished annual American Heart Association (AHA) 2021 Scientific Sessions on November 13-15. The abstracts were based on studies conducted at Nationwide Children’s Hospital and Ohio State University Hospital in Columbus, OH.

Two of the published abstracts discussed utilizing myocardial strain to detect myocardial abnormalities in young athletes post-COVID-19 infection. The third abstract focused on Multisystem Inflammatory System in Children (MIS-C), evaluating strain measurements to detect abnormalities despite normal ejection fraction levels, uncovering myocardial dysfunction.

These abstracts display MyoStrain’s unique ability to detect myocardial abnormalities that often go undetected by traditional imaging –  a potentially tremendous impact on the detection and monitoring of the effects of COVID.

Links to the abstracts are provided below:

Heyniger J, et al. Reduced Myocardial Strain is Associated with Myocardial Inflammation and Fibrosis on Cardiovascular Magnetic Resonance Imaging in Collegiate Athletes Recovering from SARS-CoV-2 Infection. AHA Scientific Sessions 2021.

Lee M, et al. Evidence of Occult Global and Regional Myocardial Strain Abnormalities in Adolescent Athletes After COVID-19 Infection. AHA Scientific Sessions 2021.

Lee S, et al. Regional Strain Abnormalities Despite Normal Ejection Fraction Suggestive of Occult Myocardial Dysfunction in Multisystem Inflammatory Syndrome in Children. AHA Scientific Sessions 2021.

Media Contact

Taylor Solomon
PR@myocardialsolutions.com
919.623.0973

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 500 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.